Status:

RECRUITING

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

Lead Sponsor:

AbbVie

Conditions:

Non-Segmental Vitiligo (NSV)

Alopecia Areata

Eligibility:

All Genders

12+ years

Brief Summary

This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppur...

Eligibility Criteria

Inclusion

  • Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)
  • Participants Ability to understand study questionnaires, with caregiver support as required for adolescents

Exclusion

  • Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)
  • Unable or unwilling to comply with study requirements and PRO collection

Key Trial Info

Start Date :

September 2 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 1 2027

Estimated Enrollment :

2795 Patients enrolled

Trial Details

Trial ID

NCT07136467

Start Date

September 2 2025

End Date

August 1 2027

Last Update

December 24 2025

Active Locations (88)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 22 (88 locations)

1

Buenos Aires Skin /ID# 277637

Buenos Aires, Argentina, 1055

2

Centro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 277634

Buenos Aires, Argentina, 1061

3

Hospital Italiano de Buenos Aires /ID# 277636

Buenos Aires, Argentina, 1181

4

Instituto de Neumonología y Dermatología /ID# 277635

Buenos Aires, Argentina, 1425

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa | DecenTrialz